Invest and Sell Generate Biomedicines Stock

Generate Biomedicines Funding Rounds and Valuation

Funding History Chart

Funding Round Details

	Funding Date	Share Class	Amount Raised	Price per Share	Post-Money Valuation	Key Investors
	09/24/2024	Series C	$288MM	$xx.xx	$1.95B	Amgen, NVentures, MAPS Capital, Pictet Alternative Advisors, Flagship Pioneering, Abu Dhabi Investment Authority, Fidelity, T. Rowe Price, ARCH Venture Partners, March Capital, Alaska Permanent Fund, Altitude Life Science Ventures, Novartis
Price per Share $xx.xx Shares Outstanding 24,303,797 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Cumulative Participating Non-participating Participation Cap N/A Key Investors Amgen, NVentures, MAPS Capital, Pictet Alternative Advisors, Flagship Pioneering, Abu Dhabi Investment Authority, Fidelity, T. Rowe Price, ARCH Venture Partners, March Capital, Alaska Permanent Fund, Altitude Life Science Ventures, Novartis
	11/18/2021	Series B	$373.42MM	$xx.xx	$1.52B	Alaska Permanent Fund, Altitude Life Science Ventures, ARCH Venture Partners, T. Rowe Price, Flagship Pioneering
Price per Share $xx.xx Shares Outstanding 31,512,642 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Cumulative Participating Non-participating Participation Cap N/A Key Investors Alaska Permanent Fund, Altitude Life Science Ventures, ARCH Venture Partners, T. Rowe Price, Flagship Pioneering
	09/10/2020	Series A	$40.25MM	$xx.xx	$89.44MM	Flagship Pioneering
Price per Share $xx.xx Shares Outstanding 40,250,000 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate Cumulative Non-cumulative Participating Non-participating Participation Cap N/A Key Investors Flagship Pioneering

Access Stock Price

Leadership & Board

Leadership

Jason Silvers

Chief Financial Officer

Gevorg Grigoryan Ph.D

Co-Founder & Chief Technology Officer

Beth Grous

Chief People Officer

Dimitris Agrafiotis Ph.D

Chief Digital Officer

Alexandra Snyder MD

Chief Medical Officer & Executive Vice President of Research & Development

Michael Nally

Co-Chief Executive Officer

Geoffrey von Maltzahn Ph.D

Co-Founder & Co-Chief Executive Officer

Molly Gibson Ph.D

Co-Founder & Chief Strategy and Innovation Officer

Sean Martin JD

Chief Legal Officer & General Counsel

Noubar Afeyan Ph.D

Co-Founder

Generate Biomedicines stock FAQs

Can you buy Generate Biomedicines stock?

As Generate Biomedicines is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Generate Biomedicines, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy Generate Biomedicines stock?

To invest in a private company like Generate Biomedicines through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Generate Biomedicines stock?

Yes, you may sell the Generate Biomedicines stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Generate Biomedicines stock?

If you hold private company shares of Generate Biomedicines – whether as an employee or an early investor – Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Generate Biomedicines on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

Is Generate Biomedicines a public company?

No, Generate Biomedicines is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Generate Biomedicines’ stock price?

Generate Biomedicines is a privately held company and therefore does not have a public stock price. However, you may access Generate Biomedicines private market stock price with Forge Data.

What is Generate Biomedicines’ stock ticker symbol?

Generate Biomedicines does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Generate Biomedicines’ news and media highlights

The Boston Globe 11/15/2023

Generate Bio raises $273 million to keep growing

Generate Biomedicines, based in Somerville, has raised $273 million in its latest funding round, despite a decline in biotech investments this year. The company, which uses AI for drug discovery, received funding from previous investors including Abu Dhabi Investment Authority and Fidelity Management & Research Company, as well as from new sources. Generate Biomedicines has raised nearly $700m in equity financing since 2020 and plans to use the new capital to bring other drug programs into clinical and preclinical testing stages.

Benzinga 11/15/2023

Generate:Biomedicines Announces Publication of its Chroma Model in Nature: A Transformative Generative AI for Protein Therapeutics

Generate:Biomedicines announced the publication of its Chroma AI model in Nature. The model can program novel proteins with unique properties. The company is also making the model available to the broader research community to accelerate scientific progress in generative biology. The open-source software can help develop novel protein molecules with therapeutic properties, potentially speeding up protein design developments.

crunchable news 09/15/2023

The Week's 10 Biggest Funding Rounds: Databricks And Generate Biomedicines Lead Another AI Surge

Databricks and Generate Biomedicines led the week's 10 largest funding rounds, with the former raising $500m in a Series I round and the latter raising $273m in a Series C round. Other significant funding rounds included Lyten which raised $200m in a Series B round, and EquipmentShare which raised $150m. AI-related startups featured prominently in this week's funding.

BioSpace 09/14/2023

Generate Raises $273M in Series C Financing with New Investors Amgen, NVIDIA

AI-focused startup Generate:Biomedicines has raised $273 million in Series C financing with new investors including Amgen and NVIDIA’s venture capital arm, the Massachusetts-based biotech announced Thursday.

Browse More Insights

Updated on: Nov 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

Generate Biomedicines Stock

Register To Buy and Sell Private Company Shares

Enterprise Value

Access Generate Biomedicines’ valuation and stock price.

Generate Biomedicines Stock Price